Reducing Fracture Risk in Postmenopausal Osteoporosis: a Review of Effective and Safe Pharmacological Therapy Providing Adherence to Treatment

Abstract

INTRODUCTION. Postmenopausal osteoporosis (PMO) accounts for up to 85 % of all cases of osteoporosis, complications of which — pathological fractures — lead to a decrease in quality of life and functionality, pain, severe psycho-emotional disorders, loss of ability to self-care, disability and an increased risk of death. Timely prescribed pathogenetic therapy for osteoporosis, including in patients undergoing medical rehabilitation, helps reduce the risk of developing osteoporotic fractures and prevent complications associated with them.
 MAIN CONTENT OF THE REVIEW. The literature review analyzes 5 domestic and 47 foreign literary sources, on the basis of which a description of modern methods of treating PMO is made in order to reduce the risk of developing pathological fractures. Poor patient adherence to osteoporosis therapy is associated with low effectiveness of PMО treatment and an increased financial burden on the healthcare system — increased hospitalization rates and treatment costs. The infrequent dosing frequency and good tolerability of therapy help to increase adherence to oral supplements.
 CONCLUSION. The review focused on the effectiveness and safety of the oral bisphosphonate ibandronic acid 150 mg once a month, the administration of which to women with PMO demonstrated good tolerability, ease of use and high efficiency, both in reducing the risk of fractures and in increasing bone mineral density, including long-term treatment periods — 5 years.